List View

By /

Clear

Displaying 2,501 - 2,525 of 2,995

K-RAS Therapies in NSCLC

K-RAS Therapies in NSCLC

Other Driver Mutations: ROS-1, BRAF, MET and RET

Other Driver Mutations: ROS-1, BRAF, MET and RET

Non Driver NSCLC: The Immunotherapy Strategy

Non Driver NSCLC: The Immunotherapy Strategy

Small Cell Lung Cancer: Targeting This Difficult Target

Small Cell Lung Cancer: Targeting This Difficult Target

Novel Advances in T-Cell NHL Therapies

Novel Advances in T-Cell NHL Therapies

What Is New for DLBCL and & Hodgkin’s Disease?

What Is New for DLBCL and & Hodgkin’s Disease?

Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy

Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy

CLL: Therapeutic Advances in 2024

CLL: Therapeutic Advances in 2024

Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)

Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)

De Novo Acute Myeloid Leukemia

De Novo Acute Myeloid Leukemia

CAR-T Cell Therapy in Lymphomas: 7-Years Later

CAR-T Cell Therapy in Lymphomas: 7-Years Later

Novel Therapeutic Strategies for MDS Based on Molecular Profile

Novel Therapeutic Strategies for MDS Based on Molecular Profile

Acquired Inhibitors in Cancer: State-of-the Art Management

Acquired Inhibitors in Cancer: State-of-the Art Management

Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy

Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy

Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients

Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients

Sequencing Therapy in Relapsed/Refractory Myeloma Patients

Sequencing Therapy in Relapsed/Refractory Myeloma Patients

Clinical Update: Cell and Gene Therapy, the Future of Medicine

Clinical Update: Cell and Gene Therapy, the Future of Medicine

The Art and the Science of Formulary Management | Acute to Ambulatory Strategies

The Art and the Science of Formulary Management | Acute to Ambulatory Strategies

Clinical Update: Biosimilars to Adalimumab

Clinical Update: Biosimilars to Adalimumab

Minimizing Waste by Maximizing BUDs: Immediate Use Compounding for Biologics

Minimizing Waste by Maximizing BUDs: Immediate Use Compounding for Biologics

Policy Update - Financial Survival: It’s not Easy Being Green!!

Policy Update - Financial Survival: It’s not Easy Being Green!!

PD-1 Inhibitor Update

PD-1 Inhibitor Update

Clinical and Practice Considerations in the Management of Iron Deficiency Anemia

Clinical and Practice Considerations in the Management of Iron Deficiency Anemia

White Bagging & The Movement for Policy Development

White Bagging & The Movement for Policy Development

Clinical Update: Malignant Hematology

Clinical Update: Malignant Hematology